Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Revenue (2016 - 2025)

Historic Revenue for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to $20.0 million.

  • Theravance Biopharma's Revenue rose 1850.84% to $20.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $80.3 million, marking a year-over-year increase of 2711.58%. This contributed to the annual value of $64.4 million for FY2024, which is 1211.51% up from last year.
  • As of Q3 2025, Theravance Biopharma's Revenue stood at $20.0 million, which was up 1850.84% from $26.2 million recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Revenue registered a high of $26.2 million during Q2 2025, and its lowest value of $2.5 million during Q1 2022.
  • For the 5-year period, Theravance Biopharma's Revenue averaged around $14.7 million, with its median value being $14.5 million (2024).
  • As far as peak fluctuations go, Theravance Biopharma's Revenue skyrocketed by 85046.67% in 2021, and later tumbled by 8246.48% in 2022.
  • Theravance Biopharma's Revenue (Quarter) stood at $14.9 million in 2021, then decreased by 1.99% to $14.6 million in 2022, then increased by 19.91% to $17.6 million in 2023, then rose by 6.77% to $18.8 million in 2024, then grew by 6.59% to $20.0 million in 2025.
  • Its Revenue was $20.0 million in Q3 2025, compared to $26.2 million in Q2 2025 and $15.4 million in Q1 2025.